While assisted reproductive technologies have allowed millions of couples to have children, their success rates have not increased dramatically. Treatment of infertility related to ovarian function have not developed over the last past 25 years. This project ties directly into increased agency and health of women as it increases the possibility for family planning. We have identified a drug, NTY001, which can help to mature egg, independent of hormones. This has a major impact on women not benefitting from the hormone treatment given today, or do not tolerate the treatment, due to disease and/or age. We have shown proof of concept of efficacy in aged female mice, where NTY001 treatment successfully made the female mice pregnant and resulted in life birth. We are now in the progress of providing additional proof of concept in aged non-human primates, as a translational model for mono-ovulatory species, like human. We will monitor egg formation, fertilisation rates and embryo development in the primates treated with NTY001. Further to this, we will generate an endocrine profile, measuring hormones before and after treatment, to evaluate the safety, as well, in the non-human primates. We wish to take this invention et step closer to the bed side, and with the non-human primate results, we expect to enter the clinical phase 1a ultimo 2023.